Clinical Trials
Search documents
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Globenewswire· 2025-07-31 20:00
Core Points - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [1][6] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for treating adult patients with MASH [6] Financial Summary - As of June 30, 2025, the liquidity account had cash resources of €428,212.57, with a total of 84,532 shares available [3] - The number of executions on the buy side for the semester was 1,642, with a traded volume of 267,584 shares for €744,692.94, while the sell side had 1,878 executions and a traded volume of 296,504 shares for €819,771.51 [3] - The previous half-year report as of December 31, 2024, indicated cash resources of €349,630.55 and 113,452 shares available [3] Trading Activity - The trading activity for the buy side included various dates with notable volumes, such as 2,741 shares traded for €5,865.74 on February 1, 2025, and 2,000 shares for €4,580.00 on February 10, 2025 [2][4] - The sell side also showed significant activity, with 14,338 shares traded for €34,267.82 on January 23, 2025, and 9,521 shares for €26,373.17 on February 24, 2025 [2][4] Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq Global Market, indicating its presence in both European and American markets [7] - The company aims to address significant unmet medical needs through its innovative therapies, particularly focusing on chronic liver diseases [6]
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
The Motley Fool· 2025-07-22 08:14
Core Insights - Positive results from clinical trials can significantly impact pharmaceutical companies' stock prices, but long-term investors should consider broader factors for sustained performance [1] Eli Lilly - Eli Lilly reported positive phase 3 results for its oral GLP-1 candidate, orforglipron, focusing on diabetes patients with A1c reduction as the primary endpoint [4] - The company is expected to release data from late-stage studies for orforglipron in obesity within the next year, which could be pivotal for its market success [5] - Despite potential risks, Eli Lilly's stock is considered a buy due to its strong financial performance and a robust pipeline, including other candidates like retatrutide [6][7] Summit Therapeutics - Summit Therapeutics is developing ivonescimab, a cancer treatment already approved in China, and is conducting trials to support approval in the U.S. and Europe [8] - A key late-stage trial against Merck's Keytruda for non-small cell lung cancer (NSCLC) is ongoing, with top-line data expected by the end of next year [9] - The stock price is sensitive to trial results; positive outcomes could significantly boost the stock, while disappointing results may lead to declines [10][11] Vertex Pharmaceuticals - Vertex Pharmaceuticals focuses on developing breakthrough medicines for high unmet needs, including a candidate for type 1 diabetes (T1D), zimislecel, which shows promise in early trials [13] - In a phase 1/2 trial, 10 of 12 patients were insulin-free after one year, and the company plans to submit regulatory applications for zimislecel by 2026 [14] - Vertex continues to lead in cystic fibrosis treatments and has expanded its portfolio with new medicines, positioning itself well for future growth [15][16]
